摘要
目的:探讨替格瑞洛对经皮冠状动脉介入术(PCI)术后血清IL-6、TNF-α水平变化。方法:选取2014年4月至2016年3月在我院行PCI治疗的患者180例,将患者随机分为观察组(n=98)和对照组(n=82),观察组口服替格瑞洛,对照组口服氯吡格雷,检测两组治疗前后IL-6、TNF-α、高敏C反应蛋白(hs-CRP)和可溶性白细胞分化抗原40配体(s CD40L)以及血小板最大聚集率(MPAR)。结果:观察组术后1 d、7 d和28 d IL-6、TNF-α、hs-CRP和s CD40L均明显低于对照组(P<0.05);观察组治疗后1 d、7 d和28 d MPAR分别为(54.10±12.51)%、(41.03±13.20)%和(30.81±9.78)%,明显低于对照组(P<0.05);观察组和对照组主要心血管不良事件发生率分别为1.02%和2.44%,差异比较无统计学意义(P>0.05)。结论:替格瑞洛能显著降低PCI术后血清炎症因子水平,抗血小板聚集和血管保护作用较好。
Objective： To investigate the effect of ticagrelor on interleukin-6（ IL-6）,tumor necrosis factor-αafter percutaneous coronary intervention（ PCI） treatment. Methods： From April 2014 and March 2016,180 patients with PCI in our hospital were randomly divided into observation group（ n = 98） and control group（ n =82）. The control group was treated with clopidogrel,the observation group ticagrelor. IL-6,TNF-α,high sensitive C reactive protein（ hs-CRP） and soluble cell differentiation antigen 40 Ligand（ s CD40L） and maximum platelet aggregation rate（ MPAR） were detected inthe two groups before and after treatment. Results： 1 d,7 d and 28 d in the observation group after treatment,IL-6,TNF-α,hs-CRP and s CD40 L were significantly lower than those in the control group（ P〈0. 05）; MPAR were（ 54. 10 ± 12. 51） %,（ 41. 03 ± 13. 20） % and（ 30. 81 ± 9. 78） % 1 d,7 d and 28 d after treatment in the observation group,significantly lower than those in the control group（ P〈0. 05）; The incidence of major adverse cardiovascular events in the observation group and the control group were6. 12% and 9. 76%,the difference was not statistically significant（ P〉0. 05）. Conclusion： Ticagrelor can significantly reduce serum levels of inflammatory factors after PCI with good anti platelet aggregation and vascular protective effects.
出处
《现代医学》
2017年第6期785-789,共5页
Modern Medical Journal
